Original Publication Date: 26 February, 2014
Publication / Source: Immunotherapy
Authors: Adam J Adler & Anthony T Vella
The mainstay therapies for patients with advanced cancer have long been radiation and chemotherapeutics that exact substantial adverse effects on healthy tissue. Fortunately, the recent revolution in our understanding of the molecular, biochemical and immunological properties of tumors has facilitated the development of rational approaches that target tumors, but not healthy cells, with greater precision. An excellent example is the development of small molecule inhibitors that target an oncogenic driver mutation in the BRAF signaling protein expressed within the majority of melanomas .